Literature DB >> 22194375

Liquid embolization material reduces the delivered radiation dose: clinical myth or reality?

F Bing1, R Doucet, F Lacroix, J P Bahary, T Darsaut, D Roy, F Guilbert, J Raymond, A Weill.   

Abstract

BACKGROUND AND
PURPOSE: To be radiopaque, BAVM embolization products must contain high-atomic-number materials, which may also attenuate photon beams delivered with radiosurgery. This "shielding effect" has been invoked to explain why radiation therapy may be less effective for previously embolized BAVMs. To evaluate the impact of embolization material on radiation dose, we measured and compared the dose delivered to the center of an AVM model, before and following embolization with various materials in a LINAC.
MATERIALS AND METHODS: Two in vitro AVM models were constructed by drilling interconnected tubular perforations in plastic water phantoms to simulate nidal vessels. Phantoms were designed to allow the positioning of a radiation detector at their center. One model was embolized with Onyx 18 and a second model, with a combination of Indermil, Lipiodol, tungsten powder, and Onyx 18. The radiation delivered was compared between embolized and nonembolized controls following irradiation with a standard 250-cGy dose.
RESULTS: The mean dose of radiation delivered to the model embolized with Onyx alone was 244 ± 5 cGy before and 246 ± 5 cGy following embolization. The mean dose of radiation delivered to the model embolized with various agents was 242 ± 5 cGy before, and 254 ± 5 cGy after embolization.
CONCLUSIONS: Embolic material did not reduce the radiation dose delivered by a LINAC to the center of our experimental BAVM models. The shielding effect may be compensated by scattered and reflected radiation.

Entities:  

Mesh:

Year:  2011        PMID: 22194375      PMCID: PMC7964822          DOI: 10.3174/ajnr.A2943

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  22 in total

1.  Analysis of the causes of treatment failure in gamma knife radiosurgery for intracranial arteriovenous malformations.

Authors:  Y Kwon; S R Jeon; J H Kim; J K Lee; D S Ra; D J Lee; B D Kwun
Journal:  J Neurosurg       Date:  2000-12       Impact factor: 5.115

2.  Radiosurgical treatment planning of AVM following embolization with Onyx: possible dosage error in treatment planning can be averted.

Authors:  Natan Shtraus; Dan Schifter; Benjamin W Corn; Shimon Maimon; Shlomi Alani; Vladimir Frolov; Diana Matceyevsky; Andrew A Kanner
Journal:  J Neurooncol       Date:  2010-04-10       Impact factor: 4.130

3.  Liquid embolisation material reduces the delivered radiation dose: a physical experiment.

Authors:  Y M Andrade-Souza; M Ramani; D J Beachey; D Scora; M N Tsao; K Terbrugge; M L Schwartz
Journal:  Acta Neurochir (Wien)       Date:  2008-01-23       Impact factor: 2.216

4.  Definition of the key target volume in radiosurgical management of arteriovenous malformations: a new dynamic concept based on angiographic circulation time.

Authors:  Ramiro Del Valle; Marco Zenteno; José Jaramillo; Angel Lee; Salvador De Anda
Journal:  J Neurosurg       Date:  2008-12       Impact factor: 5.115

5.  Endovascular treatment increases but gamma knife radiosurgery decreases angiogenic activity of arteriovenous malformations: an in vivo experimental study using a rat cornea model.

Authors:  Akin Akakin; Abdulkadir Ozkan; Emel Akgun; Demet Yalcinkaya Koc; Deniz Konya; M Necmettin Pamir; Turker Kilic
Journal:  Neurosurgery       Date:  2010-01       Impact factor: 4.654

6.  Prediction of obliteration of arteriovenous malformations after radiosurgery: the obliteration prediction index.

Authors:  M Schwartz; K Sixel; C Young; A Kemeny; D Forster; L Walton; E Franssen
Journal:  Can J Neurol Sci       Date:  1997-05       Impact factor: 2.104

7.  Linac radiosurgery for cerebral arteriovenous malformations: results in 169 patients.

Authors:  M Schlienger; D Atlan; D Lefkopoulos; L Merienne; E Touboul; O Missir; F Nataf; H Mammar; K Platoni; P Grandjean; J N Foulquier; J Huart; C Oppenheim; J F Meder; E Houdart; J J Merland
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-15       Impact factor: 7.038

8.  Hypoxia-inducible factor and vascular endothelial growth factor are expressed more frequently in embolized than in nonembolized cerebral arteriovenous malformations.

Authors:  Ulrich Sure; Elmar Battenberg; Astrid Dempfle; Wuttipong Tirakotai; Siegfried Bien; Helmut Bertalanffy
Journal:  Neurosurgery       Date:  2004-09       Impact factor: 4.654

Review 9.  A randomized trial of unruptured brain arteriovenous malformations (ARUBA).

Authors:  J P Mohr
Journal:  Acta Neurochir Suppl       Date:  2008

10.  Inhibition of angiogenesis induced by cerebral arteriovenous malformations using gamma knife irradiation.

Authors:  Kaya Kiliç; Deniz Konya; Ozlem Kurtkaya; Aydin Sav; M Necmettin Pamir; Türker Kiliç
Journal:  J Neurosurg       Date:  2007-03       Impact factor: 5.115

View more
  6 in total

1.  Dosimetric effects of embolization material artefacts in arteriovenous malformations stereotactic radiosurgery on treatment planning calculation.

Authors:  Abousaleh Elawadi; Mukhtar Alshanqity; Hussain AlHussain; Reham Mohamed; Yasser Orz; Sultan Alqahtani; Sayel Melheim
Journal:  Phys Imaging Radiat Oncol       Date:  2022-07-02

2.  Embolization before Gamma Knife radiosurgery for cerebral arteriovenous malformations does not negatively impact its obliteration rate: a series of 190 patients.

Authors:  Mehdi Yahia-Cherif; Chifra Fenton; Thomas Bonnet; Olivier De Witte; Stéphane Simon; Viviane De Maertelaer; Benjamin Mine; Florence Lefranc; Boris Lubicz
Journal:  Neuroradiology       Date:  2022-10-22       Impact factor: 2.995

3.  Embolization and radiosurgery for arteriovenous malformations.

Authors:  Andres R Plasencia; Alejandro Santillan
Journal:  Surg Neurol Int       Date:  2012-04-26

4.  Stereotactic radiosurgery with versus without prior Onyx embolization for brain arteriovenous malformations.

Authors:  Ching-Jen Chen; Dale Ding; Cheng-Chia Lee; Kathryn N Kearns; I Jonathan Pomeraniec; Christopher P Cifarelli; David E Arsanious; Roman Liscak; Jaromir Hanuska; Brian J Williams; Mehran B Yusuf; Shiao Y Woo; Natasha Ironside; Rebecca M Burke; Ronald E Warnick; Daniel M Trifiletti; David Mathieu; Monica Mureb; Carolina Benjamin; Douglas Kondziolka; Caleb E Feliciano; Rafael Rodriguez-Mercado; Kevin M Cockroft; Scott Simon; Heath B Mackley; Samer G Zammar; Neel T Patel; Varun Padmanaban; Nathan Beatson; Anissa Saylany; John Y K Lee; Jason P Sheehan
Journal:  J Neurosurg       Date:  2020-12-11       Impact factor: 5.408

5.  Endovascular and microsurgical treatment of cerebral arteriovenous malformations: Current recommendations.

Authors:  Andrew Conger; Charles Kulwin; Michael T Lawton; Aaron A Cohen-Gadol
Journal:  Surg Neurol Int       Date:  2015-03-19

6.  Treatment of Brain AVMs (TOBAS): study protocol for a pragmatic randomized controlled trial.

Authors:  Tim E Darsaut; Elsa Magro; Jean-Christophe Gentric; André Lima Batista; Chiraz Chaalala; David Roberge; Michel W Bojanowski; Alain Weill; Daniel Roy; Jean Raymond
Journal:  Trials       Date:  2015-11-04       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.